These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 6272974)
1. Summary: symposium on Epstein-Barr virus-induced lymphoproliferative diseases in immunodeficient patients. Klein G; Purtilo D Cancer Res; 1981 Nov; 41(11 Pt 1):4302-4. PubMed ID: 6272974 [No Abstract] [Full Text] [Related]
2. Introduction to Epstein-Barr virus and lymphoproliferative diseases in immunodeficient individuals. Purtilo DT; Klein G Cancer Res; 1981 Nov; 41(11 Pt 1):4209. PubMed ID: 6272963 [No Abstract] [Full Text] [Related]
3. T-cell control of herpesvirus infections: lessons from the Epstein-Barr virus. Rickinson AB Prog Brain Res; 1983; 59():189-202. PubMed ID: 6320264 [No Abstract] [Full Text] [Related]
4. Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients. Purtilo DT; Tatsumi E; Manolov G; Manolova Y; Harada S; Lipscomb H; Krueger G Int Rev Exp Pathol; 1985; 27():113-83. PubMed ID: 3017882 [No Abstract] [Full Text] [Related]
5. Immune deficiency predisposing to Epstein-Barr virus-induced lymphoproliferative diseases: the X-linked lymphoproliferative syndrome as a model. Purtilo DT Adv Cancer Res; 1981; 34():279-312. PubMed ID: 6269372 [No Abstract] [Full Text] [Related]
6. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Saemundsen AK; Purtilo DT; Sakamoto K; Sullivan JL; Synnerholm AC; Hanto D; Simmons R; Anvret M; Collins R; Klein G Cancer Res; 1981 Nov; 41(11 Pt 1):4237-42. PubMed ID: 6272968 [TBL] [Abstract][Full Text] [Related]
13. Long-term T-cell-mediated immunity to Epstein-Barr virus. Rickinson AB; Moss DJ; Wallace LE; Rowe M; Misko IS; Epstein MA; Pope JH Cancer Res; 1981 Nov; 41(11 Pt 1):4216-21. PubMed ID: 6272965 [No Abstract] [Full Text] [Related]
14. Immunopathology of infectious mononucleosis and other complications of Epstein-Barr virus infections. Purtilo DT Pathol Annu; 1980; 15(Pt 1):253-99. PubMed ID: 6255399 [No Abstract] [Full Text] [Related]
15. [Epstein-Barr virus. Its participation in lymphoproliferative and anaplastic processes]. Fejes M; Bachmann AE; Mochanko K Medicina (B Aires); 1978; 38(6 Pt 1):700-16. PubMed ID: 220495 [No Abstract] [Full Text] [Related]
16. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. Thorley-Lawson DA J Immunol; 1980 Feb; 124(2):745-51. PubMed ID: 6243331 [TBL] [Abstract][Full Text] [Related]
17. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis. Klein E; Ernberg I; Masucci MG; Szigeti R; Wu YT; Masucci G; Svedmyr E Cancer Res; 1981 Nov; 41(11 Pt 1):4210-5. PubMed ID: 6272964 [TBL] [Abstract][Full Text] [Related]
18. [Role of the Epstein-Barr virus in human pathology]. Rupniewska ZM Acta Haematol Pol; 1979; 10(3):183-91. PubMed ID: 228518 [No Abstract] [Full Text] [Related]
19. [Epstein-Barr virus and its role in various rheumatic diseases]. Anan'eva LP; Alekberova ZS; Barinskii IF; Nasonova VA Ter Arkh; 1983; 55(7):140-6. PubMed ID: 6312625 [No Abstract] [Full Text] [Related]
20. The changing faces of EBV research. Klein G; Klein E Prog Med Virol; 1984; 30():87-106. PubMed ID: 6087416 [No Abstract] [Full Text] [Related] [Next] [New Search]